Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?

Non-alcoholic fatty liver disease (NAFLD) is a common finding in obese people, especially patients with type 2 diabetes (T2DM). It may progress to non-alcoholic steatohepatitis (NASH) and ultimately fibrosis and cirrhosis (1-3). Because of the epidemics of both obesity and T2DM, the prevalence of NAFLD will increase, potentially causing a tremendous clinical and economic burden (4).